Dr. de Blank graduated from the University of California, San Francisco School of Medicine with a concentration in Medical Education. He completed his residency in Pediatrics, and fellowships in Pediatric Hematology & Oncology and Pediatric Neuro-Oncology at the Children’s Hospital of Philadelphia. He completed a Masters of Science in Clinical Epidemiology and Biostatistics at the University of Pennsylvania during his fellowship training. After completing his training, he became a faculty member at University Hospitals Rainbow Babies & Children’s Hospital in Cleveland in 2012. In 2017, Dr. de Blank joined the faculty at Cincinnati Children’s Hospital Medical Center as a member of the Pediatric Neuro-Oncology program.
Dr. de Blank’s clinical and research interests include children with central nervous system tumors, neurofibromatosis type 1 (NF1), and NF1-related tumors. His research focuses on the investigation of tissue microstructure in pediatric brain tumors through non-invasive imaging techniques such as MR relaxometry and diffusion tensor imaging. The goal of his research is to develop early radiographic tumor biomarkers to characterize pediatric brain tumors and predict their functional consequences. Tumor imaging research may guide early intervention efforts and direct support for children with brain tumors in order to improve clinical outcomes in children with brain tumors.
Dr. de Blank has been elected by peers for inclusion in the Best Doctors in America List.
BA: Stanford University, Stanford, CA, 1997.
BS: Chemistry, Stanford University, Stanford, CA, 1997.
MA: Stanford University, Stanford, CA, 1997.
MD: Emphasis in Medical Education, University of California, San Francisco School of Medicine, San Francisco, CA, 2005.
MS: Clinical Epidemiology, University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA, 2011.
Intern: Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2005-2006.
Resident: Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2006-2008.
Fellow: Pediatric Hematology and Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2008-2011; Pediatric Neuro-Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2011-2012.
Pediatric neuro-oncology; neurofibromatosis type 1 (NF1); NF1-associated brain tumors
Cancer and Blood Diseases, Brain Tumor, Rasopathy, Neurofibromatosis
Cancer imaging; diffusion tensor imaging; MR relaxometry; magnetic resonance fingerprinting; developmental therapeutics
Cancer and Blood Diseases, Oncology
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Opportunities and Advances in Radiomics and Radiogenomics for Pediatric Medulloblastoma Tumors. Diagnostics. 2023; 13:2727.
An unusual presentation of bilateral optic pathway glioma in Crouzon Syndrome. Pediatric Hematology-Oncology (Informa). 2023; ahead-of-print:1-7.
MDB-44. A TRANSFER LEARNING APPROACH FOR AUTOMATIC SEGMENTATION OF TUMOR SUB-COMPARTMENTS AND TUMOR HABITAT IN PEDIATRIC MEDULLOBLASTOMA. Neuro-Oncology. 2023; 25:i71-i72.
DIPG-52. EXTRAPONTINE PROGRESSION WITH STABLE PONTINE DISEASE POST-RADIOTHERAPY IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) ON A CONNECT TRIAL: IMPLICATIONS FOR RADIATION TREATMENT VOLUMES. Neuro-Oncology. 2023; 25:i25.
DIPG-54. UPDATED FINDINGS FROM THE PHASE IB STUDY OF UNESBULIN (PTC596) IN CHILDREN WITH NEWLY-DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT). Neuro-Oncology. 2023; 25:i25-i26.
MDB-43. GRADIENT ENTROPY-BASED RADIOMIC RISK-SCORE FROM T1-WEIGHTED PRE-TREATMENT MRI SCANS CAN PREDICT SURVIVAL IN PEDIATRIC MEDULLOBLASTOMA. Neuro-Oncology. 2023; 25:i71.
Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis. Nature. 2022; 612:787-794.
Novel MRI deformation-heterogeneity radiomic features are associated with molecular subgroups and overall survival in pediatric medulloblastoma: Preliminary findings from a multi-institutional study. Frontiers in Oncology. 2022; 12:915143.
NIMG-16. COMPARISON OF A STIR- AND T1-WEIGHTED-BASED RADIOMICS MODEL TO DIFFERENTIATE BETWEEN PLEXIFORM NEUROFIBROMAS AND MALIGNANT PERIPHERAL NERVE SHEATH TUMORS IN NEUROFIBROMATOSIS TYPE 1 (NF1). Neuro-Oncology. 2022; 24:vii164-vii165.